Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.
about
Second-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancerSecond-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancerIncreased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancerEmerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.Effects of taxol resistance gene 1 on the cisplatin response in gastric cancer.Multifaceted Roles for Macrophages in Prostate Cancer Skeletal Metastasis.
P2860
Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.
@en
Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.
@nl
type
label
Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.
@en
Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.
@nl
prefLabel
Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.
@en
Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.
@nl
P2093
P2860
P1433
P1476
Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.
@en
P2093
Antonella Venturino
Franco Checcaglini
Giuseppe Colloca
P2860
P2888
P304
P356
10.1007/S12032-011-9855-6
P577
2011-02-20T00:00:00Z